Today’s top gainers include the company Mylan N.V. (NASDAQ:MYL) which is in the industry Drugs – Generic, gaining 1.62% today. In the last week its performance is 2.65%, and -7.73% for the past quarter. Currently, Mylan N.V., MYL has a target price of 56.71, so today’s gain of 1.62% is a significant step towards its target price. The GAP today is therefore 1.22%.
Mylan N.V. (NASDAQ:MYL), has a market cap of 22618.27, and is based in USA. Insider ownership is at 0.50%, and institutional ownership is 64.50%.
At the current price of 42.59, it has a dividend yield of *TBA, and its target price is 56.71. This is with a profit margin of 8.10%, and total debt/equity of 1.31. Mylan N.V. (NASDAQ:MYL) has a P/E of 27.08, as well as a forward P/E of 7.39.
With a current EPS of 1.57, and a forecasted EPS growth for next year at 16.34%,Mylan N.V. (NASDAQ:MYL) has had a EPS growth for the past five years at 20.20%. For the next five years EPS growth is projected to be 13.26%.
Performance for the year is -6.21%. Since its IPO date on 12/18/1987, the total performance to date is -21.23%.
Volume today for Mylan N.V. (NASDAQ:MYL), is 7727500, while its average volume is 5717.62. Whilst the total gain today was 1.62%, it did have a day high of -15.50%.
Volatility for this week has been at 2.53%, and 3.14% for the month. The 52-week low for Mylan N.V., MYL has been 13.30%, while the 52-week-high has reached -23.28%.
Looking at its return of investments, which is 8.20%, and its return on assets is 3.40%. Mylan N.V. (NASDAQ:MYL) has an operating margin of 15.70%. With a sales growth of 8.00% quarter over quarter. Bearing in mind that Mylan N.V., MYL is in the sector Healthcare, its long-term debt/equity is 1.24, and has a current ratio of 3.2 and 2.6 for quick ratio.
So what is the value of Mylan N.V.? Well its PEG is 2.04, and the P/S is 2.28, along with a P/B of 2.08. Meanwhile it has a p/cash of 3.56.